A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Richardson, Paul G.
Polepally, Akshanth R.
Motwani, Monica
Mu, Yunming
Salman, Zeena
Penugonda, Sudhir
Moreau, Philippe
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137037
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
    Biran, Noa
    Siegel, David
    Berdeja, Jesus G.
    Raje, Noopur
    Cornell, Robert Frank
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy S.
    Landgren, Ola
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
  • [42] PRELIMINARY DATA OF THE ONGOING OPEN-LABEL, SINGLE-ARM PHASE II STUDY OF MP0250 IN COMBINATION WITH BORTEZOMIB plus DEXAMETHASONE IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
    Goldschmidt, H.
    Raab, M. S.
    Duerig, J.
    Szarejko, M.
    Jurczyszyn, A.
    Grzasko, N.
    Vacca, A.
    Bringhen, S.
    D'Agostino, M.
    Gamberi, B.
    Haunschild, J.
    Hermann, F.
    Fiedler, U.
    Dawson, K.
    Harstrick, A.
    Acosta, J.
    Schreder, M.
    Knop, S.
    HAEMATOLOGICA, 2018, 103 : 13 - 13
  • [43] A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
    Martin, Thomas
    Baz, Rachid
    Benson, Don M.
    Lendvai, Nikoletta
    Wolf, Jeffrey
    Munster, Pamela
    Lesokhin, Alexander M.
    Wack, Claudine
    Charpentier, Eric
    Campana, Frank
    Vij, Ravi
    BLOOD, 2017, 129 (25) : 3294 - 3303
  • [44] A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
    Mikhael, Joseph
    Richardson, Paul
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Karanes, Chatchada
    Campana, Frank
    Kanagavel, Dheepak
    Dubin, Franck
    Liu, Qianying
    Semiond, Dorothee
    Anderson, Kenneth
    BLOOD, 2019, 134 (02) : 123 - 133
  • [45] Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Lonial, Sagar
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Otero, Paula Rodriguez
    Pineiro, Luis
    Jakubowiak, Andrzej
    Olyslager, Yunsi
    Wang, Jianping
    Nnane, Ivo
    Ukropec, Jon
    Shreeve, Martin
    Qi, Ming
    Moreau, Philippe
    BLOOD, 2019, 134
  • [46] PANORAMA 2: A PHASE II STUDY OF PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED AND BORTEZOMIB-REFRACTORY MULTIPLE MYELOMA
    Richardson, P.
    Alsina, M.
    Weber, D.
    Coutre, S.
    Lonial, S.
    Gasparetto, C.
    Warsi, G.
    Ondovik, M.
    Mukhopadhyay, S.
    Paley, C.
    Schlossman, R.
    HAEMATOLOGICA, 2012, 97 : 338 - 338
  • [47] Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial
    Beksac, Meral
    Richardson, Paul
    Oriol, Albert
    Lindsay, Jindriska
    Schjesvold, Fredrik
    Galli, Monica
    Yagci, Munci
    Larocca, Alessandra
    Weisel, Katja
    Yu, Xin
    Donahue, Cynthia
    Acosta, Jorge
    Peluso, Teresa
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S27 - S28
  • [48] Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Richardson, Paul G.
    Jagannath, Sundar
    Moreau, Philippe
    Jakubowiak, Andrzej
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    White, Darrell
    Reece, Donna E.
    Benboubker, Lotfi
    Zonder, Jeffrey
    Tsao, L. Claire
    Anderson, Kenneth C.
    Bleickardt, Eric
    Singhal, Anil K.
    Lonial, Sagar
    BLOOD, 2014, 124 (21)
  • [49] VENETOCLAX (ABT-199/GDC-0199) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 1B RESULTS
    Moreau, P.
    Chanan-Khan, A. A.
    Roberts, A.
    Agarwal, A.
    Facon, T.
    Lebovic, D.
    Touzeau, C.
    Darden, D.
    Morris, L.
    Ross, J.
    Salem, A.
    Munasinghe, W.
    Zhu, M.
    Leverson, J.
    Enschede, S.
    Humerickhouse, R.
    Harrison, S.
    HAEMATOLOGICA, 2015, 100 : 91 - 92
  • [50] Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study
    Bringhen, Sara
    Oliva, Stefania
    Liberati, Anna Marina
    Belotti, Angelo
    Larocca, Alessandra
    Bonello, Francesca
    Gaidano, Gianluca
    Bertazzoni, Paola
    Esma, Fabrizio
    Stocchi, Raffaella
    Malfitano, Alessandra
    Ribolla, Rossella
    Di Sano, Chiara
    Aschero, Simona
    Patriarca, Francesca
    De Paoli, Lorenzo
    Cafro, Anna Maria
    Sonneveld, Pieter
    Palumbo, Antonio
    Boccadoro, Mario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E59 - E59
12345